There have been revolutionary advancements in the prosthetic heart valves, such as development of transcatheter heart valves and tissue heart valves. This has increased the adoption of prosthetic heart valves among patients and healthcare providers.
Global Prosthetic Heart Valve Market was valued at $3,874 million in 2016, and is expected to reach at $8,392 million by 2023, growing at a CAGR of 11.4%. Prosthetic heart valve is a device implanted in a patient suffering from valvular heart disease, which results in malfunction of one or more valves (out of a total four valves) present in the human heart. The treatment for such disease includes replacement of a natural heart valve with a prosthetic heart valve.
Rise in prevalence of cardiac disorders, such as rheumatic heart diseases, increase in geriatric population, change in lifestyle of people, novel technological advancements in prosthetic heart valves, increase in patient awareness, demand for minimally invasive cardiovascular surgeries, and rise in number of transcatheter heart valve surgery centers drive the market growth. However, high cost and risk associated with prosthetic heart valves and stringent approval process (as formulated by FDA and other regulatory bodies) for prosthetic heart valves restrain the market growth.
Get the PDF brochure of this market study@ https://www.alliedmarketresearch.com/request-sample/2176
The growth opportunities in emerging countries of Asia-Pacific and LAMEA and use of transcatheter heart valves for new indications (treatment of intermediate-risk patients and high risk patients) are expected to provide numerous opportunities for the market growth during the forecast period.
Prosthetic heart valves are implanted in patients suffering from valvular heart disease, which results in failure of one or more valves present in the human heart. These patients are treated by replacing a natural heart valve with a prosthetic heart valve.
Rise in incidence of structural heart diseases and rapid adoption of prosthetic valves drive the growth of the prosthetic valves market in LAMEA. There is an increase in prevalence of cardiac disorders, such as aortic stenosis in the Latin America due to lack of efficient treatment systems in these countries. In addition, the Latin American countries have reduced gross income leading to less expenditure on the development of new methods and devices, resulting in increase in need for efficient treatment systems. This increase in demand has attracted several key players from the West to invest in the Brazilian market for the growth of their transcatheter heart valve business. Israel offers an emerging market for transcatheter heart valve implantation procedure, owing to increase in geriatric population and rise in demand for unmet treatment procedures, which boost the market growth. Lack of facilities and an increased need for treatment devices have drawn the key players to invest in the Middle Eastern market.
Do Purchase Inquiry@ https://www.alliedmarketresearch.com/purchase-enquiry/2176
The prosthetic valves market has witnessed several clinical trials in the recent years. Transcatheter valves accounted for the highest number of clinical trials in the market, owing to their high durability and lower requirement for anticoagulation therapy. The European countries conduct maximum number of clinical trials as a result of high prevalence of heart diseases, such as aortic stenosis and mitral regurgitation. For instance, in Europe, more than 1.75 million people suffer from aortic stenosis. In addition, mechanical valves trials were highest in Europe (about 45.6%) followed by North America (38.1%).
The list of key players profiled in this report include Abbott Laboratories, Medtronic plc., Medical Technology Est., Boston Scientific Corporation, Micro Interventional Devices, Inc., Direct Flow medical, Inc., Edwards Lifesciences Corporation, LivaNova PLC., JenaValve Technology, Inc., and Cryolife, Inc.
Key players in the value chain include Corvia Medical, Inc., CardioKinetix, Inc., Biomerics, LLC., Lepu Medical Technology (Beijing) Co., Ltd., XELTIS BV, Comed B.V., HLT, Inc., Meril Life Sciences Pvt. Ltd., SYMETIS SA, and Transcatheter Technologies GmbH.